4//SEC Filing
Arkowitz David 4
Accession 0000950170-24-016687
CIK 0001609809other
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 9:13 PM ET
Size
16.1 KB
Accession
0000950170-24-016687
Insider Transaction Report
Form 4
Arkowitz David
Chief Financial Officer
Transactions
- Award
Restricted Stock Units
2024-02-14+35,625→ 35,625 total→ Common Stock (35,625 underlying) - Award
Stock Option (Right to Buy)
2024-02-14+213,750→ 213,750 totalExercise: $1.10Exp: 2034-02-13→ Common Stock (213,750 underlying) - Exercise/Conversion
Restricted Stock Units
2024-02-15−10,625→ 31,875 total→ Common Stock (10,625 underlying) - Exercise/Conversion
Common Stock
2024-02-15+10,625→ 186,381 total - Sale
Common Stock
2024-02-16$1.08/sh−3,939$4,254→ 182,442 total - Award
Stock Option (Right to Buy)
2024-02-14+287,905→ 287,905 totalExercise: $1.10Exp: 2034-02-13→ Common Stock (287,905 underlying)
Footnotes (7)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F3]The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
- [F5]The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively.
- [F6]The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- [F7]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Documents
Issuer
Seres Therapeutics, Inc.
CIK 0001609809
Entity typeother
Related Parties
1- filerCIK 0001296999
Filing Metadata
- Form type
- 4
- Filed
- Feb 15, 7:00 PM ET
- Accepted
- Feb 16, 9:13 PM ET
- Size
- 16.1 KB